HOME >> BIOLOGY >> NEWS
Innovative method for gene therapy of heart disease shows promise in animal studies

Philadelphia, Pa. Heart disease patients may someday receive a dose of gene therapy that would protect injured coronary arteries from further damage and possibly even treat the underlying heart disease. The genes would be delivered to artery walls by stents, the tiny metal scaffolds that are now implanted in diseased arteries to hold the vessels open for improved blood flow.

In cell cultures and in pigs, a team led by a researcher from The Childrens Hospital of Philadelphia showed that genes in DNA added to the stents were transferred into cells on the artery wall. The study appeared in the November issue of the journal Nature Biotechnology.

"This is the first example of gene transfer in an animal model using stents for DNA delivery," said Robert J. Levy, M.D., director of the Pediatric Cardiology Research Laboratory at The Childrens Hospital of Philadelphia. "The technique has major implications for treating coronary artery disease with gene therapy."

Stents are commonly used in angioplasty procedures for partially blocked coronary arteries. After a small balloon is inserted through a catheter and inflated to widen a narrowed artery (the angioplasty procedure), an expandable wire scaffolding (the stent) is left in the artery to keep it open. However, in approximately 30 percent of patients, stents injure the artery, causing cells to grow back within a few months, often forming new obstructions.

The gene delivery technique employed by Dr. Levys team would release a gene or combination of genes that can help control blood vessel damage by inhibiting cell growth in the artery walls. "Further research is needed to identify genes that would have the most beneficial effect," said Dr. Levy, "but this study in animals shows that the gene delivery technique is possible."

Delivery is a crucial problem in any gene therapy approach. Unlike other approaches that uses viruses as delivery vehicles to carry genes into the body, Dr. Levys group uses DNA w
'"/>

Contact: Maria Stearns
stearnsm@email.chop.edu
215-590-4091
Children's Hospital of Philadelphia
7-Nov-2000


Page: 1 2

Related biology news :

1. Innovative ceramic-on-metal hip replacements to undergo clinical trials
2. Innovative efforts target epigenetics, molecular imaging
3. Innovative self healing bandage to help diabetics
4. Innovative shuttle bus debuts in Washington, D.C.
5. Innovative research with pythons offers new insights into the bodys digestive processes
6. Vaccination following spinal cord injury: Innovative Weizmann Institute approach limits paralysis
7. Innovative Process To Benefit Ground Water Clean-Up
8. Exotic Species, Migratory Birds, Sea Level Rise, Wetlands, And Contaminants...USGS Scientists Discuss Innovative Chesapeake Bay Restoration Studies
9. UF Researchers Innovative Fence Helps Control Sand Flies
10. ACS Conference Brief: An Innovative Molecular Assembly
11. Cystic Fibrosis Foundation Launches Innovative Therapeutics Development Centers

Post Your Comments:
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
Cached News: